Table 3.

Subgroup analyses of efficacy and safety outcomes.

	Efficacy				Safety
	Mean monthly headache days, baseline to week 12		Mean monthly migraine days, baseline to week 12		At least one adverse event		At least one adverse event related to trial regimen		At least one serious adverse event
	MD, 95% CI	P-value	MD, 95% CI	P-value	RR, 95% CI	P-value	RR, 95% CI	P-value	RR, 95% CI	P-value
Dose regimens
Monthly	−2.85 (−4.32, 1.38)	0.0001	−2.27 (−3.52, −1.01)	0.0004	1.22 (1.01, 1.47)	0.04	1.36 (1.12, 1.65)	0.002	0.70 (0.33, 1.47)	0.35
Quarterly	−2.55 (−4.02, −1.08)	0.0007	−2.00 (−3.17, −0.83)	0.0008	1.34 (1.11, 1.62)	0.002	1.30 (1.07, 1.58)	0.007	0.47 (0.20, 1.09)	0.08
Subgroup differences	P = 0.78		P = 0.86		P = 0.48		P = 0.74		P = 0.48
Types of migraine
CM	−1.99 (−2.55, −1.43)	0.0001	−2.43 (−3.70, −1.17)	0.0002	1.12 (1.03, 1.21)	0.01	1.37 (0.91, 2.06)	0.13	0.93 (0.36, 2.37)	0.87
EM	−1.90 (−2.88, −0.92	0.0001	−2.36 (−3.55, −1.17)	0.0001	1.08 (0.89, 1.31)	0.44	1.25 (1.07, 1.47)	0.005	1.58 (0.06, 41.14)	0.78
Subgroup differences	P = 0.88		P = 0.93		P = 0.75		P = 0.69		P = 0.76
Preventive medications
No more than 2 used	−1.97 (−2.45, −1.48)	0.0001	−1.77 (−2.29, −1.25)	0.0001	1.12 (1.04, 1.20)	0.003	1.23 (1.11, 1.36)	0.0001	0.94 (0.35, 2.53)	0.91
2–4 used	−3.40 (−4.18, −2.62)	0.0001	−3.30 (−4.08, −2.52)	0.0001	1.04 (0.90, 1.21)	0.58	1.02 (0.76, 1.36)	0.91	0.75 (0.21, 2.63)	0.65
Subgroup differences	P = 0.002		P = 0.001		P = 0.42		P = 0.22		P = 0.78